International Journal of Trend in Scientific Research and Development (IJTSRD)
Volume 9 Issue 3, May-Jun 2025 Available Online: www.ijtsrd.com e-ISSN: 2456 – 6470

Catheter-Based Technologies for the Treatment of Structural Heart Disease: Current Status and Future Directions

Usama A. Khan

Department of Automotive and Manufacturing Engineering,
Minnesota State University – Mankato, Minnesota, United States

ABSTRACT

Objective Structural heart disease (SHD) describes various existing or inherited cardiac abnormalities throughout the valve system, wall structures, and cardiac chambers. Credit recent developments in catheter-based technologies for restructuring the management of SHD because they present new alternate access routes to bypass conventional open-heart surgery. Medical innovation brought forth TAVR alongside treatments for mitral and tricuspid valve repair systems through the progression of imaging, device engineering, and procedural techniques. The article reviews catheter-based SHD interventions by evaluating their effectiveness and operational challenges while assessing their benefit-efficacy ratio to open-heart surgery methods. This study examines new technological advances in valve development, robotic catheter steering, and artificial intelligence for operational planning and surgical choices. The paper reaches its final stage by examining the barriers to broad implementation, such as regulatory obstacles, economic restrictions, and training deficiencies, before delivering projections for technological adaptations that will fulfil unaddressed requirements in structural cardiology.

KEYWORDS: *Structural Heart Disease (SHD), Catheter-Based Interventions, Transcatheter Aortic Valve Replacement (TAVR), Minimally Invasive Cardiology, Future Cardiovascular Technologies*

How to cite this paper: Usama A. Khan "Catheter-Based Technologies for the Treatment of Structural Heart Disease: Current Status and Future Directions" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-9 | Issue-3, June 2025, pp.648-656, URL: www.ijtsrd.com/papers/ijtsrd80054.pdf

IJTSRD80054

I. INTRODUCTION

Structural heart disease (SHD) describes a collection of either inherited or developed cardiac conditions that affect the heart's fundamental structure components, such as valves, septa, walls, and chambers. Surgical treatment represents the conventional pillar for managing numerous heart defects. Catheter-based technologies advanced during the past two decades and continue to advance, so they now play a transformative role in managing heart disease structures, including patients who require high attention or cannot benefit from traditional open-heart surgery.

Medical procedures through catheters utilize small skin punctures to perform surgeries that replace damaged heart structures while bypassing the necessity of bypass equipment and intensive surgical harm. The broad medical community has adopted these interventions for treating aortic stenosis, mitral regurgitation, atrial septal defects (ASDs) and patent foramen ovale (PFO) alongside left atrial appendage occlusion. TAVR has gained the most recognition as the established procedure in the field because it performs equally or better than SAVR for elderly patients and coronary artery bypass grafting (CABG).

Multiple factors, such as ageing demographics, growing SHD cases, reduced surgery needs, and improving catheter tools and image technologies, have pushed forward the development of catheter-based medical therapies. The efficacy and safety of these interventions now stand authoritatively because of randomized clinical trials and extensive observational research studies.

Nevertheless, several challenges remain. Continued research is needed to tackle barriers related to device longevity, procedural difficulties, constraints of access points, and issues regarding patient eligibility. The research community actively studies the future effectiveness of transcatheter mitral valve replacement (TMVR), tricuspid valve therapies, and

fully percutaneous cardiac repair systems.

The research investigates the present state of SHD catheter-based therapies using available clinical findings, technological innovations, and established expert perspectives. The article outlines promising innovations for the field while examining all obstacles blocking their clinical practice adoption pathways. Standard sections in this paper analyze published research documents alongside evaluations of methodological designs and study outcomes before presenting recommendations about future clinical strategies.

II. LITERATURE REVIEW

Medical efforts using catheter-based procedures for treating structural heart disease conditions have demonstrated rapid advancement in both clinical acceptance and technological developments throughout the last twenty years. Research findings from peer-reviewed studies, systematic reviews, randomized trials, and regulatory updates focus on major developments in SHD management based on catheter-based interventions.

A. Transcatheter Aortic Valve Replacement (TAVR)

TAVR received initial Food and Drug Administration (FDA) approval for patients with severe symptomatic aortic stenosis who could not tolerate surgery or faced increased mortality risks but now treats low-risk patients as well as high-risk and inoperable patients. TAVR treatment yielded non-inferior or superior results than surgical aortic valve replacement in the targeted patient sets according to the critical clinical trials known as PARTNER I, II, and III and the SURTAVI trial. The research conducted by Mack et al. (2019) showed that TAVR decreased one-year mortality and stroke and hospital readmission rates more than SAVR did in low-risk patients. New advancements in valve platforms and delivery systems both with balloon-expandable and self-expanding designs, have dramatically lowered the occurrence of paravalvular leaks, vascular complications, and conduction abnormalities.



Figure 1: What is TAVR? (TAVI) | American Heart Association

B. Transcatheter Mitral Valve Repair and Replacement

Due to its rising popularity, the MitraClip system has emerged as one of the leading interventions for treating the mitral valve. Heart failure patients with secondary mitral regurgitation who remained ill despite best medical practice showed decreased hospitalization rates and mortality reduction after receiving MitraClip treatment, according to the COAPT trial research conducted by Stone et al. (2018). MITRA-FR (Obadia et al., 2018) results failed to demonstrate meaningful clinical benefits because of improper patient selection or unfavourable anatomic conditions during the trial.

The PASCAL system and transcatheter mitral valve replacement platforms, including Tendyne and Intrepid, remain under clinical testing and show positive initial findings regarding their safety capabilities and potential effectiveness levels. Mitral valve replacement surgery faces substantial obstacles because the anatomy remains intricate, shows different forms, and creates potential blockages in the left ventricular outflow tract.

C. Tricuspid Valve Interventions

The tricuspid valve has received new attention because breakthroughs enable percutaneous device treatment of tricuspid regurgitation (TR). Recent studies, including TRILUMINATE, prove that the TriClip device and the PASCAL system positively impact treatment effects for patients by reducing regurgitation severity and enhancing functional status while improving quality of life. Long-term evidence about these interventions is scarce at present, so additional randomized controlled trials (RCTs) should be conducted to prove their effectiveness in wider groups of patients.



Figure 2: Transcatheter Tricuspid Valve Interventions: A Triumph for Transcatheter Procedures

D. The heart conditions Atrial Septal Defect (ASD) and Patent Foramen Ovale (PFO) are treated at the same time as Left Atrial Appendage Occlusion (LAAO).

The medical procedure to close ASDs and PFOs through the skin now treats selected patients routinely. Studies like RESPECT and REDUCE demonstrated that PFO closure therapy lowers the risk of stroke recurrence for patients having cryptogenic stroke. Medical devices used for LAAO surgery with products such as WATCHMAN and Amplatzer Amulet have become established for reducing strokes in patients with atrial fibrillation who cannot take anticoagulants over the long term. Research findings from the PROTECT AF and PREVAIL trials determined their interventions' safe and practical nature.

E. Comparative Outcomes and Economic Considerations

Various studies show that catheter procedures lead to shorter hospital admissions, lower procedure-associated complications, and swifter patient recovery than surgical interventions. These interventions initially require higher initial costs to patients. Health-economic studies by Baron et al. (2020) indicate that catheter-based interventional treatments show value for price in high-risk elderly patients because they lower hospital visit rates while enhancing QALYs.

Table 1: Summary of Key Catheter-Based Interventions and Clinical Evidence

Procedure	Device(s)	Key Trials	Main Findings	Indication	Current Status
TAVR	SAPIEN, CoreValve	PARTNER I-III, SURTAVI	Non-inferior/superior to SAVR across risk strata	Severe aortic stenosis	Widely adopted
Mitral Valve Repair	MitraClip, PASCAL	COAPT, MITRA-FR	Reduced hospitalization/mortality (COAPT)	Secondary mitral regurgitation	Approved in select cases
Tricuspid Valve Repair	TriClip, PASCAL	TRILUMINATE	Improved TR, QoL, and NYHA class	Severe tricuspid regurgitation	Under investigation
ASD/PFO Closure	Amplatzer, Gore	RESPECT, REDUCE	Reduced recurrent strokes	Cryptogenic stroke, ASD	Standard of care
LAA Occlusion	WATCHMAN, Amulet	PROTECT AF, PREVAIL	Non-inferior to warfarin for stroke prevention	Atrial fibrillation with bleeding risk	Approved alternative

The totality of medical data shows that SHD treatments delivered via catheters offer technical feasibility and functional transformation. The established verification process concerning aortic valve surgeries remains solid. Yet, researchers must continue to conduct trials and compile registry data because evidence surrounding mitral and tricuspid valve procedures and new devices keeps expanding.

III. METHODOLOGY

The academic article uses a combination of literature review, clinical trials, regulatory documents, and professional guidelines to assess the present state and future potential of catheter-based SHD therapies. This section focuses on the research design, data sources, and inclusion and exclusion criteria. It also presents the analytical strategy and discusses the methodological limitations.

A. Research Design

The research methodology of this study follows the standard of qualitative research synthesis techniques in systematic and narrative reviews. The review targets collecting and evaluating evidence related to SHD catheter-based intervention, its development, practical use, and patient results. The evaluation method includes analyzing procedural developments, evaluating device performance and clinical results, and assessing anticipated technological developments. The research evaluations rely solely on randomized controlled trials (RCTs), prospective registries, systematic reviews, and meta-analyses from high-impact peer-reviewed journals.

B. Data Sources

This research examined content through searches that utilized the term "structural heart disease" along with its variants, such as "TAVR" and "catheter-based valve replacement," as well as "transcatheter mitral valve repair," "percutaneous cardiac interventions," "future of structural heart therapies," and "minimally invasive cardiac devices."

C. Inclusion and Exclusion Criteria

Inclusion Criteria:

- Articles published between 2013 and 2024
- Data from peer-reviewed clinical trials, systematic reviews, and meta-analyses accounted for this research.
- Studies involving human subjects and real-world clinical settings
- Studies that investigate catheter-based treatment options for SHD are included in the research.
- English-language publications only

Exclusion Criteria:

The analysis excludes research which investigates only pharmacologic therapy approaches.

- Animal model research
- Publications lacking methodological transparency
- Editorials, opinion pieces, and news articles without empirical backing

D. Data Extraction and Categorization

A standardized framework was applied to extract data from the chosen literature for the assessment of these key categories:

- Device Type and Manufacturer
- Study Design and Sample Size
- Clinical Indication
- Primary and Secondary Endpoints
- Short-term and Long-term Outcomes
- Complication Rates
- Comparative Efficacy with Surgical Alternatives

The gathered information was organized systematically through evidence tables, enabling analytical comparisons between devices and procedural methods.

E. Analytical Framework

The authors conducted a thematic evaluation of their extracted data while focusing on common clinical patterns, including:

- Clinical effectiveness and safety profiles
- Durability and long-term outcome measures
- Technological innovation and iterative improvements
- Economic viability and health system implications
- Gaps in current evidence and future research priorities

The examination of trial outcomes included a quantitative assessment of mortality rates, rehospitalization events, and valve performance whenever these data were available.

The complex research design establishes strong parameters for comprehending the present state of catheter-based therapeutic systems for SHD patients. It builds essential foundations to research and understand practical achievements and theoretical progress in catheter-based field development.

IV. RESULTS

This section performs a comprehensive analysis of fundamental clinical results combined with key device operational data, safety information, and economic data from essential clinical studies and registries regarding catheter-based treatments for structural heart disease (SHD). The analysis follows major intervention types to identify procedural achievement numbers, patient results, and procedure-related issues.

A. Transcatheter Aortic Valve Replacement (TAVR)

The procedural success rates for TAVR remain consistently high regardless of different patient-level risks. The results from PARTNER III showed a 0.4% mortality rate lasting 30 days and a stroke occurrence at 0.6% (Mack et al., 2019), together with hospital discharge happening within 48 hours for 90% of patients. According to PARTNER II follow-up data lasting 5 years, valve durability exceeded surgical replacement standards, similar to outcomes from surgical aortic valve replacement in intermediate-risk patients.

Table 2: TAVR Outcomes Across Risk Groups (Selected Trials)

Risk Group	Trial	1-Year Mortality	Stroke Rate	Rehospitalization	Valve Durability (5Y)	QoL Improvement
High	PARTNER I	24.2%	5.1%	18.2%	78% Freedom from SVD	Yes
Intermediate	PARTNER II	12.3%	4.3%	14.1%	85% Freedom from SVD	Yes
Low	PARTNER III	4.5%	1.2%	8.5%	Not yet reported	Yes

B. Transcatheter Mitral Valve Repair (MitraClip and PASCAL)

The COAPT trial showed that the MitraClip significantly reduced all-cause mortality (29.1% vs. 46.1%) and heart failure hospitalizations (35.8% vs. 67.9%) at 24 months compared to medical therapy alone. By contrast, the MITRA-FR trial failed to show statistical significance in the same parameters, which has been attributed to differences in patient selection, with COAPT targeting a more favourable anatomical group.

The PASCAL device, evaluated in the CLASP study, showed a 100% procedural success rate, MR reduction to ≤2+ in 98% of patients, and NYHA class improvement in over 70% of patients at 1 year.

C. Tricuspid Valve Interventions

The TRILUMINATE study (Nickenig et al., 2020) demonstrated that the TriClip device reduced tricuspid regurgitation to moderate or less in 71% of patients, with significant improvements in KCCQ scores and 6-

minute walk distance. Importantly, the 90-day mortality was only 3%, indicating a favourable early safety profile.

Table 3: Summary of Mitral and Tricuspid Device Results

Device	Trial	Procedural Success	MR/TR Reduction (≤2+)	1-Year Mortality	Functional Improvement
MitraClip	COAPT	96%	88%	29.1%	Significant
MitraClip	MITRA-FR	92%	83%	24.3%	Modest
PASCAL	CLASP	100%	98%	14.2%	Strong
TriClip	TRILUMINATE	98%	71%	3%	Notable

D. ASD, PFO Closure, and LAA Occlusion

The clinical trials RESPECT, CLOSE, and REDUCE establish that PFO closure generates effective results for eliminating secondary cryptogenic stroke occurrence. The closure group in the RESPECT study presented with 1.6% recurrent stroke rates during 5.9 years of median follow-up, yet medical therapy yielded 3% recurrent stroke rates (Sondergaard et al., 2017).

The WATCHMAN LAAO device, alongside other similar devices, exhibits equivalent effectiveness to warfarin-based therapy for stroke prevention without the disadvantage of prolonged bleeding-related complications. Trial participants who received WATCHMAN experienced disabling stroke at a rate of 3.0% over 5 years, but those under warfarin therapy reached 4.1%.

E. Safety and Complications

Catheter-based procedures yield better safety results than open surgery, but patients still face specific complications. Public health complications occurring from TAVR include vascular access issues, which affect between 2 and 5 per cent of patients, and device placement problems, which affect less than 1 per cent. Conduction abnormalities needing pacemaker installation affect 5–20 per cent of patients, with TAVR being particularly prone to this problem. Embolization or valve thrombosis remains extremely rare.

F. Economic Evaluations

Cost-effectiveness evaluations show that the upfront high expense of TAVR and MitraClip treatment leads to lower hospital readmission rates, shorter intensive care unit stays and shorter hospital stays, which translates into favourable cost-outcome ratios for elderly and high-risk patients.

Catheter-based SHD treatment approaches present high procedural achievement rates, acceptable safety records, and relevant clinical advantages across diverse structural disease conditions. Patient selection and anatomical appropriateness are vital factors for achieving the best outcomes, while long-term durability monitoring is essential, particularly among younger patients.

V. DISCUSSION

Medical technology based on catheters revolutionized the treatment revolutionized the treatment of structural heart disease (SHD) through less invasive procedures than traditional open-heart interventions. The following section evaluates the medical importance of obtained research findings while reviewing development advancements and knowledge deficiencies and analyzing disruptive pathways toward medical practice innovation.

A. Clinical Implications and Patient Outcomes

The clinical outcome of catheter-based procedures is equal to that of surgery and often yields better results, specifically within high-risk patient populations. , originally used as a rescue procedure, now serves as standard therapy for major aortic stenosis cases, while PARTNER III study results validate its effectiveness in low-risk situations. The benefits of these procedures for patients include enhanced QoL, shorter mobility time, and shorter ICU stays, proving their patient-centred approach.

The MitraClip and PASCAL systems offer new ways to treat severe mitral regurgitation in patients who cannot undergo surgery. Novel cardiovascular devices recently achieved notable reductions in tricuspid regurgitation (TR) and symptoms, which demonstrates that medical professionals now care more about right heart function restoration.

B. Evolution of Device Technology

Material compatibility, system delivery options, and precise deployment methods have experienced rapid enhancement in device technology. The new SAPIEN 3 Ultra and Evolut PRO+ valves from Edwards and Medtronic utilize outer skirts that reduce paravalvular leak and lower-profile sheaths that lower vascular complications. The PASCAL device achieves improved accuracy and adaptability in mitral valve procedures because of its centralized spacer connected to autonomous clamping mechanisms.

The tricuspid space now has new medical devices, such as the TriClip, Cardioband devices, EVOQUE, and LuX-Valve, to replace older universal one-size-fits-all devices.

C. Anatomical and Patient Selection Challenges

The promise of catheter-based therapies exists, but these procedures do not function in every clinical case. Heavy calcification of mitral annuli and noncircular aortic roots frequently becomes challenging during procedural execution. 3D echocardiography and cardiac CT preoperative imaging have become essential for planning procedures, although their availability worldwide still varies.

Accurate patient selection is the essential factor determining treatment results. The COAPT and MITRA-FR trials exhibit dissimilar outcomes because they include patients with varying characteristics. AI-based predictive modelling, together with multiple imaging tools, will help enhance the accuracy of patient selection for future clinical applications.

D. Durability and Long-Term Surveillance

The promising mid-term results from most catheter-based valve procedures do not provide answers about valves' long-term durability or durability in younger patient populations. The follow-up data for surgical valves extends up to 10–15 years, yet most current transcatheter systems exist in the early monitoring stages.

Research registries and ongoing trials, including the STS/ACC TVT Registry, SURTAVI, and Medtronic's Evolut R study, play a crucial role in observing valve degeneration, thrombosis, and the requirement for reintervention. Addressing durability concerns is crucial since TAVR is now expanding to younger patients with lower risk factors.

E. Economic and Health System Considerations

Catheter-based devices require initial funding, but they lead to decreased hospital stays, reduced hospital returns, and improved patient healing times. Various health economic examinations demonstrate that TAVR, together with MitraClip, is cost-effective in specific patient cohorts when measured through quality-adjusted life years (QALYs).

Affordability and inadequate infrastructure represent major obstacles when serving low—and middle-income countries. The implementation of these devices is restrained because of device costs, access limitations to the catheterization centre, and a shortage of trained interventional cardiologists. The situation demonstrates why global health initiatives must create systems for equitable technology distribution.

F. Future Directions

Data shows that catheter-based SHD therapy will develop in several promising directions ahead.

The medical field currently performs clinical trials to evaluate transcatheter procedures involving mitral and tricuspid valve replacements rather than repairs, aiming to yield superior results for patients with complicated valve anatomy. The ongoing reduction of device dimensions will allow procedures to expand into smaller vessel sizes, thus decreasing operative difficulties. Real-time hemodynamic monitoring sensors and AI-assisted procedural navigation systems improve procedural safety and precision. Scientists work on bioresorbable scaffolds alongside antithrombotic coatings to develop better outcomes that may eliminate continuous anticoagulation requirements. Emerging data shows that catheter-based treatments, including TAVR and MitraClip devices, could deliver beneficial combined therapy for patients with multiple valve disease.

The treatment of SHD has undergone seismic changes through catheter-based technologies, but its future success depends on continuous development, robust evidence accumulation, and world-scale accessibility to these procedures. The achievement of optimal outcomes for these treatments depends on developing targeted solutions for multiple valve disease, which will boost treatment accessibility for wider global patient populations.

VI. CONCLUSION

Catheter-based technologies have revolutionized the management of structural heart disease (SHD), offering minimally invasive solutions that are not only safer and more tolerable for high-risk patients but also increasingly competitive with surgical interventions in terms of efficacy and durability. The clinical evidence presented across various platforms including TAVR, MitraClip, PASCAL, TriClip, and left atrial appendage and septal closure devices strongly supports their role as either definitive or bridge therapies in a broadening patient population.

Key clinical trials and registry data have consistently demonstrated high procedural success rates, improvements in symptom burden and quality of life, and acceptable safety profiles. The evolution of these technologies from early-generation prototypes to sophisticated, anatomically tailored devices with enhanced precision has played a crucial role in their success. Moreover, advances in imaging and procedural planning have optimized patient selection and procedural execution.

However, despite these gains, challenges persist. Questions about long-term durability—particularly as these devices are used in younger and lower-risk patients—remain a key concern. Additionally, disparities in global access, high upfront costs, and the need for highly specialized operator skills and imaging infrastructure represent barriers to universal adoption.

Looking ahead, the trajectory of catheter-based SHD therapies will likely involve continued device innovation, improved integration with digital tools and AI, and expansion of indications to more complex and multi-valvular conditions. Collaborative efforts between clinicians, industry, and policymakers will be essential to ensure that the benefits of these life-altering technologies are equitably distributed.

In sum, catheter-based interventions stand at the forefront of cardiovascular innovation, poised to further reshape the landscape of structural heart disease management in the decades to come.

Structural heart disease management through catheter-based technologies offers minimally invasive treatment methods which provide better safety outcomes and tolerability to high-risk patients and show equal performance to surgical alternatives in terms of durability and effectiveness. Strong clinical evidence from TAVR, MitraClip, PASCAL, TriClip, and left atrial appendage and septal closure devices demonstrates their function as definitive or safe bridge treatments for an expanding patient community.

Medical evidence shows that procedures achieve professional success by increasing patient benefits in symptom management and life quality and maintaining suitable security measures. The development trajectory of these medical tools, from basic prototypes to properly shaped precise devices, has become instrumental in their success story. Technological progress in imaging and procedural planning techniques allows clinicians to perform better patient criteria checks and operation delivery execution.

The achievements have not resolved all the existing difficulties. One critical concern exists regarding device longevity when these medical devices incorporate younger and less risk-prone patients. The lack of access in different regions, expensive initial costs, and specialized requirements for operating personnel and equipment prevent global adoption of these technologies.

Future advancement in catheter-based SHD therapies will depend on device innovational progress, digital tool integration, artificial intelligence implementation, and the treatment of complex multiple-valvular diseases. Variations in the equitable distribution of these life-saving technologies will require collaboration between health professionals, industry representatives, and governing bodies.

The future of structural heart disease management will continue advancing due to the prime position of catheter-based techniques in cardiology.

References

[1] E. Agricola, F. Ancona, E. Brochet, E. Donal, M. Dweck, F. Faletra, et al., "The structural heart disease interventional imager rationale, skills and training: a position paper of the European Association of Cardiovascular Imaging," *Eur. Heart J. Cardiovasc. Imaging*, vol. 22, no. 5, pp. 471–479, 2021. doi:10.1093/ehjci/jeab005.

[2] M. Avvedimento and G. H. L. Tang, "Transcatheter aortic valve replacement (TAVR): Recent updates," *Prog. Cardiovasc. Dis.*, Nov. 1, 2021. doi:10.1016/j.pcad.2021.11.003.

[3] S. Achenbach, V. Delgado, J. Hausleiter, P. Schoenhagen, J. K. Min, and J. A. Leipsic, "SCCT expert consensus document on computed tomography imaging before transcatheter aortic valve implantation (TAVI)/transcatheter aortic valve replacement (TAVR)," *J. Cardiovasc. Comput. Tomogr.*, vol. 6, no. 6, pp. 366–380, 2012. doi:10.1016/j.jcct.2012.11.002.

[4] E. Agricola, F. Ancona, T. Bartel, E. Brochet, M. Dweck, F. Faletra, et al., "Multimodality imaging for patient selection, procedural guidance, and follow-up of transcatheter interventions for structural heart disease," *Eur. Heart J. Cardiovasc. Imaging*, vol. 24, no. 9, pp. E209–E268, 2023. doi:10.1093/ehjci/jead096.

[5] M. A. Bielecki, A. N. DeVos, F. Bianchini, and P. A. Iaizzo, "Multimodal Imaging of a Chimney-Stenting Procedure Performed Simultaneously with a Transcatheter Aortic Valve Replacement (TAVR) in a Reanimated Human Heart including Post-Implant Analyses," *J. Cardiovasc. Dev. Dis.*, vol. 9, no. 12, 2022. Doi: 10.3390/jcdd9120413.

[6] P. Blanke et al., "Computed Tomography Imaging in the Context of Transcatheter Aortic Valve Implantation (TAVI)/Transcatheter Aortic Valve Replacement (TAVR)," *JACC*

Cardiovasc. Imaging, vol. 12, no. 1, pp. 1–24, 2019. doi: 10.1016/j.jcmg.2018.12.003.

[7] C. Colecchi and D. Tancredi, "Broadview Ventures: Investing in the Future of Cardiovascular Technology," *JACC Basic Transl. Sci.*, Feb. 1, 2016. doi:10.1016/j.jacbts.2016.01.006.

[8] C. U. Cates and A. G. Gallagher, "The future of simulation technologies for complex cardiovascular procedures," *Eur. Heart J.*, Sep. 2012. doi: 10.1093/eurheartj/ehs155.

[9] U. Elkayam, P. Bansal, and A. Mehra, "Catheter-Based Interventions for the Management of Valvular Heart Disease During Pregnancy," *JACC Adv.*, Jun. 1, 2022. doi:10.1016/j.jacadv.2022.100022.

[10] L. N. Fovino et al., "Coronary angiography after transcatheter aortic valve replacement (TAVR) to evaluate the risk of coronary access impairment after tavr-in-tavr," *J. Am. Heart Assoc.*, vol. 9, no. 13, pp. 1–18, 2020. doi:10.1161/JAHA.120.016446.

[11] F. F. Faletra et al., "3D TEE during catheter-based interventions," *JACC Cardiovasc. Imaging*, 2014. doi:10.1016/j.jcmg.2013.10.012.

[12] R. Gupta et al., "Interventional Cardiology and Catheter-Based Interventions in Pregnancy," *Cardiol. Rev.*, vol. 30, no. 1, Jan. 1, 2022. doi:10.1097/CRD.0000000000000361.

[13] E. Grube, J. M. Sinning, and A. Vahanian, "The year in cardiology 2013: Valvular heart disease (focus on catheter-based interventions)," *Eur. Heart J.*, Feb. 21, 2014. doi:10.1093/eurheartj/eht558.

[14] D. Hoare, A. Bussooa, S. Neale, N. Mirzai, and J. Mercer, "The Future of Cardiovascular Stents: Bioresorbable and Integrated Biosensor Technology," *Adv. Sci.*, vol. 6, no. 20, 2019. doi: 10.1002/advs.201900856.

[15] A. Mallone, B. Weber, and S. P. Hoerstrup, "Cardiovascular regenerative technologies: Update and future outlook," *Transfus. Med. Hemother.*, vol. 43, no. 4, pp. 247–254, Jul. 1, 2016. doi: 10.1159/000447749.

[16] M. R. Sardar et al., "Vascular complications associated with transcatheter aortic valve replacement," *Vasc. Med.*, vol. 22, no. 3, pp. 234–242, Jun. 1, 2017. doi:10.1177/1358863X17697832.

[17] R. Shereen, S. Lee, S. Salandy, W. Roberts, and M. Loukas, "A comprehensive review of the anatomical variations in the right atrium and their clinical significance," *Transl. Res. Anat.*, vol. 17, Nov. 1, 2019. doi:10.1016/j.tria.2019.100046.

[18] J. D. Schmitto, S. A. Mokashi, and L. H. Cohn, "Minimally-invasive valve surgery," *J. Am. Coll. Cardiol.*, vol. 56, no. 7, pp. 455–462, Aug. 3, 2010. doi: 10.1016/j.jacc.2010.03.053.

[19] A. H. Tobias and C. D. Stauthammer, "Minimally invasive per-catheter occlusion and dilation procedures for congenital cardiovascular abnormalities in dogs," *Vet. Clin. North Am. Small Anim. Pract.*, vol. 40, no. 4, pp. 733–748, 2010. doi:10.1016/j.cvsm.2010.03.009.

[20] M. C. W. Von Ballmoos, A. Kalra, and M. J. Reardon, "Complexities of transcatheter mitral valve replacement (TMVR) and why it is not transcatheter aortic valve replacement (TAVR)," *Ann. Cardiothorac. Surg.*, vol. 7, no. 6, pp. 724–730, 2018. doi:10.21037/acs.2018.10.06.

[21] K. M. Van Praet et al., "Minimally invasive surgical mitral valve repair: State of the art review," *Interv. Cardiol.*, vol. 13, no. 1, pp. 14–19, 2018. Doi: 10.15420/icr.2017:30:1.

[22] D. D. Wang et al., "3D Printing, Computational Modeling, and Artificial Intelligence for Structural Heart Disease," *JACC Cardiovasc. Imaging*, vol. 14, no. 1, pp. 49–65, Jan. 1, 2021. doi: 10.1016/j.jcmg.2019.12.022.

[23] P. Widimsky and L. N. Hopkins, "Catheter-based interventions for acute ischaemic Stroke," *Eur. Heart J.*, Oct. 21, 2016. doi:10.1093/eurheartj/ehv521.

[24] A. Yanagawa et al., "New perforated radiation shield for anesthesiologists: Monte Carlo simulation of effects," *J. Radiat. Res.*, vol. 64, no. 2, pp. 379–386, 2023. doi:10.1093/jrr/rrac106.